Zobrazeno 1 - 10
of 259
pro vyhledávání: '"Athos Bousvaros"'
Autor:
Yanjia Jason Zhang, Athos Bousvaros, Michael Docktor, Abby L. Kaplan, Paul A. Rufo, McKenzie Leier, Madison Weatherly, Lori Zimmerman, Le Thanh Tu Nguyen, Brenda Barton, George Russell, Eric J. Alm, Stacy A. Kahn
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-11 (2024)
Abstract Fecal Microbiota Transplant (FMT) has shown some success in treating inflammatory bowel diseases (IBD). There is emerging evidence that host engraftment of donor taxa is a tenet of successful FMT. We undertook a double-blind, randomized, pla
Externí odkaz:
https://doaj.org/article/eff6710f034e477a8e78cd9b4e399eff
Autor:
Nathan P Palmer, Jocelyn A Silvester, Jessica J Lee, Andrew L Beam, Inbar Fried, Vladimir I Valtchinov, Fedik Rahimov, Sek Won Kong, Saum Ghodoussipour, Helen C Hood, Athos Bousvaros, Richard J Grand, Louis M Kunkel, Isaac S Kohane
Publikováno v:
PLoS ONE, Vol 14, Iss 10, p e0222952 (2019)
BackgroundPresenting features of inflammatory bowel disease (IBD) are non-specific. We hypothesized that mRNA profiles could (1) identify genes and pathways involved in disease pathogenesis; (2) identify a molecular signature that differentiates IBD
Externí odkaz:
https://doaj.org/article/9fb54ecdb5224005bb2588996be46f10
Autor:
Naamah L Zitomersky, Benjamin J Atkinson, Sarah W Franklin, Paul D Mitchell, Scott B Snapper, Laurie E Comstock, Athos Bousvaros
Publikováno v:
PLoS ONE, Vol 8, Iss 6, p e63686 (2013)
There is extensive evidence implicating the intestinal microbiota in inflammatory bowel disease [IBD], but no microbial agent has been identified as a sole causative agent. Bacteroidales are numerically dominant intestinal organisms that associate wi
Externí odkaz:
https://doaj.org/article/dd7c33b2592d446091bd9be0c53ad9f8
Autor:
Eliseo Papa, Michael Docktor, Christopher Smillie, Sarah Weber, Sarah P Preheim, Dirk Gevers, Georgia Giannoukos, Dawn Ciulla, Diana Tabbaa, Jay Ingram, David B Schauer, Doyle V Ward, Joshua R Korzenik, Ramnik J Xavier, Athos Bousvaros, Eric J Alm
Publikováno v:
PLoS ONE, Vol 7, Iss 6, p e39242 (2012)
BACKGROUND:Pediatric inflammatory bowel disease (IBD) is challenging to diagnose because of the non-specificity of symptoms; an unequivocal diagnosis can only be made using colonoscopy, which clinicians are reluctant to recommend for children. Diagno
Externí odkaz:
https://doaj.org/article/dbee976b36a54737ac2c5bf0d90ea952
Autor:
Ying Lu, Athos Bousvaros
Publikováno v:
Pediatric Inflammatory Bowel Disease ISBN: 9783031147432
Pediatric Inflammatory Bowel Disease ISBN: 9783319492131
Pediatric Inflammatory Bowel Disease ISBN: 9781461450603
Pediatric Inflammatory Bowel Disease ISBN: 9783319492131
Pediatric Inflammatory Bowel Disease ISBN: 9781461450603
Many patients with inflammatory bowel disease (IBD) are at risk for infections at some point in their disease due to immunosuppressive therapy. Therefore, it is important to minimize the risk of infections through immunization. Current guidelines rec
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4bee32bf3bcb5c0bf8a0d46df58d7859
https://doi.org/10.1007/978-3-031-14744-9_55
https://doi.org/10.1007/978-3-031-14744-9_55
Autor:
Matthew Kowalik, Edward E. S. Nieuwenhuis, Dror S. Shouval, Michael Field, Kaiyue Peng, Hans Clevers, Aleixo M. Muise, Marla Dubinsky, Carmen Argmann, Dermot P.B. McGovern, Scott B. Snapper, Michal Mokry, Christoph Klein, Daniel Kotlarz, Elizabeth A. Spencer, Leslie Grushkin-Lerner, Fiona Powrie, Sung-Yun Pai, Holm H. Uhlig, Eric E. Schadt, Athos Bousvaros, Jodie Ouahed, Judy H. Cho
Publikováno v:
Inflamm Bowel Dis
Inflammatory Bowel Diseases. Oxford University Press
Inflammatory Bowel Diseases. Oxford University Press
Very early onset inflammatory bowel disease (VEO-IBD) is defined as IBD presenting before 6 years of age. When compared with IBD diagnosed in older children, VEO-IBD has some distinct characteristics such as a higher likelihood of an underlying monog
Autor:
Anne M. Griffiths, Anat Horesh, Liron Marcovitch, Anthony R. Otley, David R. Mack, Dan Turner, Amy E. Hale, Adi Shosberger, G Focht, Michael D. Kappelman, Robert Baldassano, Jeffrey S. Hyams, Athos Bousvaros
Publikováno v:
Journal of Pediatric Gastroenterology & Nutrition.
As part of the development of the TUMMY-UC, a patient-reported outcome (PRO) measure for pediatric ulcerative colitis (UC), we aimed to explore agreement on UC symptoms between children and their caregivers. We conducted 44 interviews with children a
Autor:
Theo Heller, Christopher Koh, Suk See DeRavin, Athos Bousvaros, Beatriz E. Marciano, Anna Strongin, Christa S. Zerbe, Steven M. Holland, Harry L. Malech, Bryan F. Curtin, Natasha Kamal
Publikováno v:
Gastroenterol Rep (Oxf)
Autor:
Jorge Amil Dias, Baruch Yerushalmi, Dan Turner, Gigi Veereman Wauters, Athos Bousvaros, G Abitbol, Rotem Sigall Boneh, Mona Boaz, Eytan Wine, J. Kierkus, Malgorzata Sladek, Johanna C. Escher, Arie Levine, Michal Kori, Ron Shaoul
Publikováno v:
Gut, 68(2), 239-247. BMJ Publishing Group
ObjectiveCrohn’s disease (CD) pathogenesis associated with dysbiosis and presence of pathobionts in the lumen, intracellular compartments and epithelial biofilms. Azithromycin is active in all three compartments. Our goal was to evaluate if azithro
Autor:
Talya L. Miller, Julia Schuchard, Adam C. Carle, Christopher B. Forrest, Michael D. Kappelman, Jeremy Adler, Rana F. Ammoury, Dorsey Bass, Julie Bass, Keith Benkov, Athos Bousvaros, Brendan Boyle, José M. Cabrera, Richard Colletti, Jill M. Dorsey, Dawn R. Ebach, Ann M. Firestine, Ajay Gulati, Edward J. Hoffenberg, Traci W. Jester, Jess L. Kaplan, Subra Kugathasan, Mark E. Kusek, Ian Leibowitz, Tiffany M. Linville, Peter Margolis, Phillip Minar, Zarela Molle Rios, Jonathan Moses, Pablo J. Palomo, Helen Pappa, Dinesh S. Pashankar, Shehzad A. Saeed, Charles M. Samson, Kelly C. Sandberg, Steven J. Steiner, Jennifer Strople, Jillian S. Sullivan, Jeanne Tung, Prateek Wali
Publikováno v:
J Pediatr
To evaluate whether Patient-Reported Outcomes Measurement Information System (PROMIS) pediatric patient-reported outcome (PRO) measures can serve as valid endpoints in a clinical trial of a chronic pediatric illness.We evaluated the responsiveness of